Ogilvie syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Common risk factors of Ogilvie's syndrome include having neurologic disorders, taking narcotic medications, and trauma. Other risk factors include systemic lupus erythematosus, alcoholism, and multiple myeloma. | |||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors for Ogilvie's syndrome include the following:<ref name="AoS">[http://archsurg.ama-assn.org/cgi/content/abstract/135/6/682 Ogilvie Syndrome as a Postoperative Complication] Patty L. Tenofsky, MD; R. Larry Beamer, MD; R. Stephen Smith, MD [http://archsurg.ama-assn.org/ Arch Surg.] 2000;135:682-687.</ref><ref name="pmid28257284">{{cite journal| author=Sreter KB, Barisic B, Popovic-Grle S| title=Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
. | journal=Int J Clin Pharmacol Ther | year= 2017 | volume= 55 | issue= 5 | pages= 442-448 | pmid=28257284 | doi=10.5414/CP202784 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28257284 }}</ref> | Common risk factors for Ogilvie's syndrome include the following:<ref name="AoS">[http://archsurg.ama-assn.org/cgi/content/abstract/135/6/682 Ogilvie Syndrome as a Postoperative Complication] Patty L. Tenofsky, MD; R. Larry Beamer, MD; R. Stephen Smith, MD [http://archsurg.ama-assn.org/ Arch Surg.] 2000;135:682-687.</ref><ref name="pmid28257284">{{cite journal| author=Sreter KB, Barisic B, Popovic-Grle S| title=Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
. | journal=Int J Clin Pharmacol Ther | year= 2017 | volume= 55 | issue= 5 | pages= 442-448 | pmid=28257284 | doi=10.5414/CP202784 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28257284 }}</ref> | ||
* Having cerebral palsy or other nervous system (neurologic) disorders | * Having cerebral palsy or other nervous system (neurologic) disorders | ||
* Taking narcotic medications | * Taking narcotic medications | ||
* Trauma | * Trauma | ||
Revision as of 15:17, 7 February 2018
| Ogilvie syndrome Microchapters
|
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ogilvie syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Ogilvie syndrome risk factors |
|
Risk calculators and risk factors for Ogilvie syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Common risk factors of Ogilvie's syndrome include having neurologic disorders, taking narcotic medications, and trauma. Other risk factors include systemic lupus erythematosus, alcoholism, and multiple myeloma.
Risk Factors
Common risk factors for Ogilvie's syndrome include the following:[1][2]
- Having cerebral palsy or other nervous system (neurologic) disorders
- Taking narcotic medications
- Trauma
- Cardiac diseases as myocardial infarction
Less common risk factors for Ogilvie's syndrome include the following:[3]
- Systemic lupus erythematosus
- Alcoholism
- Multiple myeloma
- Systemic sclerosis
References
- ↑ Ogilvie Syndrome as a Postoperative Complication Patty L. Tenofsky, MD; R. Larry Beamer, MD; R. Stephen Smith, MD Arch Surg. 2000;135:682-687.
- ↑ Sreter KB, Barisic B, Popovic-Grle S (2017). "Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome". Int J Clin Pharmacol Ther. 55 (5): 442–448. doi:10.5414/CP202784. PMID 28257284.
- ↑ García López CA, Laredo-Sánchez F, Malagón-Rangel J, Flores-Padilla MG, Nellen-Hummel H (2014). "Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge". World J Gastroenterol. 20 (32): 11443–50. doi:10.3748/wjg.v20.i32.11443. PMC 4145788. PMID 25170234.